Using neurofeedback to help reduce multiple drug use
Brain Mechanisms of Reducing Polysubstance Use Following a Novel Body-mind Intervention 2
NA · Arizona State University · NCT06324786
This study is testing if using neurofeedback during body-mind training can help people who struggle with heavy drinking, cannabis use, and daily smoking reduce their drug use.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 35 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Arizona State University (other) |
| Locations | 1 site (Phoenix, Arizona) |
| Trial ID | NCT06324786 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of neurofeedback (NF) in enhancing integrative body-mind training (IBMT) to reduce polysubstance use. Participants will engage in IBMT while receiving real-time feedback on their brain activity, specifically targeting self-control networks. The study will include individuals with a history of heavy drinking, cannabis use, and daily cigarette smoking, who do not have other psychiatric diagnoses. The goal is to determine if this combined approach can lead to improved outcomes in managing substance use disorders.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a history of heavy episodic drinking, cannabis use, and daily cigarette smoking, without other psychiatric diagnoses.
Not a fit: Patients with psychiatric disorders other than substance use disorders or those currently using illicit drugs may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a novel non-pharmacological treatment option for individuals struggling with multiple substance use disorders.
How similar studies have performed: While the use of neurofeedback in substance use treatment is emerging, this specific combination of NF and IBMT is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least 18 years old * Free of any psychiatric diagnoses or medication (besides a substance use disorder (SUD) to alcohol, tobacco, or cannabis) * In the past month, at least 4 episodes of heavy episodic drinking; at least 3 occasions of cannabis use; and daily cigarette use for at least the past month * Normal or corrected-to-normal vision * Written informed consent * No previous meditation or NF experiences Exclusion Criteria: * Any psychiatric diagnoses other than an SUD * Medical disorder(s) that may affect the central nervous system; medications that affect the central and autonomic nervous system; or a positive pregnancy test result (females) * Excluding cannabis, evidence of recent (past month) illicit drug use
Where this trial is running
Phoenix, Arizona
- YiYuan Tang — Phoenix, Arizona, United States (RECRUITING)
Study contacts
- Study coordinator: YiYuan Tang
- Email: yiyuan@asu.edu
- Phone: 4807903577
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Drug Use